Roivant Sciences Ltd. (ROIV) News

Roivant Sciences Ltd. (ROIV): $4.42

0.35 (+8.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ROIV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter ROIV News Items

ROIV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ROIV News Highlights

  • ROIV's 30 day story count now stands at 7.
  • Over the past 18 days, the trend for ROIV's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about ROIV are DECK and STAR.

Latest ROIV News From Around the Web

Below are the latest news stories about Roivant Sciences Ltd that investors may wish to consider to help them evaluate ROIV as an investment opportunity.

Roivant Sciences (ROIV) Receives a Buy from H.C. Wainwright

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Roivant Sciences (ROIV – Research Report), with a price target of $14.00. The company's shares closed last Monday at $7.20, close to its 52-week low of $5.80. According to TipRanks.com, Tsao is a 3-star analyst with an average return of 3.0% and a 39.0% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Roivant Sciences with a $14.50 average price target.

Howard Kim on TipRanks | February 15, 2022

Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update

Roivant’s newly launched subsidiary, Hemavant, entered into a licensing agreement with Eisai Co., Ltd. for exclusive global rights to the investigational agent RVT-2001, a potential first-in-class small molecule modulator of splicing factor 3B subunit 1 (SF3B1) for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromesDermavant has hired key commercial leadership positions in preparation for launch of tapinarof for psoriasis, subject to the FDA’s appr

Yahoo | February 14, 2022

Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022

Quarterly investor call and webcast scheduled for Monday, February 14 at 8:00 a.m. ETRoivant will also present at the SVB Leerink Global Healthcare Conference in February, and the Truist AI Symposium and Cowen Healthcare Conference in March BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live confe

Yahoo | February 7, 2022

Roivant Sciences (ROIV) Presents At B. Riley Securities Virtual Oncology Conference - Slideshow

The following slide deck was published by Roivant Sciences Ltd. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 28, 2022

Roivant to Present at Upcoming Investor Conferences

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at two upcoming conferences: B. Riley Securities Virtual Oncology Conference on Thursday, January 27, 2022 at 12:30 p.m. ETSVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 p.m. ET A live webcast of each presentation will be available under “Events & Presentations” on the Investors section of th

Yahoo | January 25, 2022

Roivant Sciences (ROIV) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 24, 2022

Goldman Sachs Predicts Over 60% Rally for These 3 Stocks

The key to investment success in 2022 is likely to be diversity; that is, a broad range of portfolio allocations that spread investment money across multiple sectors. In short, don’t put all of your eggs into one basket. Last year saw tremendous gains – some 29% on the S&P 500 – fueled by better-than-expected earnings. The rebound from the short, sharp 2020 COVID recession was real, but may have also given investors a distorted picture of the markets. For starters, the supply chain disruptions of the past year had the unanticipated effect of supporting earnings.

Michael Marcus on TipRanks | January 5, 2022

Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it has entered into a licensing agreement with Eisai Co., Ltd. for exclusive global rights to the investigational agent RVT-2001 (also known as H3B-8800), which will provide the lead program for a new subsidiary Vant.

GlobeNewswire | January 5, 2022

Roivant Sciences licenses transfusion-dependent anemia treatment from Eisai

No summary available.

Seeking Alpha | January 5, 2022

Roivant Sciences Ltd. (NASDAQ:ROIV) Has Recovered 19.00 Percent This Year, But Further Gains Of -40.13% Are Not Out Of The Question.

In last trading session, Roivant Sciences Ltd. (NASDAQ:ROIV) saw 0.55 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $11.96 trading at $0.11 or 0.93% at ring of the bell on the day assigns it a market valuation of $6.93B. That closing price of ROIV’s stock is … Roivant Sciences Ltd. (NASDAQ:ROIV) Has Recovered 19.00 Percent This Year, But Further Gains Of -40.13% Are Not Out Of The Question. Read More »

Marketing Sentinel | December 24, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4128 seconds.